Clinical Trial Update: Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the combination of osimertinib and necitumumab in EGFR-mutant stage IV or recurrent non-small cell lung cancer after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Portrazza (necitumumab)
• TAGRISSO (osimertinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING